Show simple item record

dc.contributor.authorConstantinou, Andreas I.en
dc.contributor.authorKamath, N.en
dc.contributor.authorMurley, J. S.en
dc.creatorConstantinou, Andreas I.en
dc.creatorKamath, N.en
dc.creatorMurley, J. S.en
dc.date.accessioned2019-11-04T12:50:22Z
dc.date.available2019-11-04T12:50:22Z
dc.date.issued1998
dc.identifier.urihttp://gnosis.library.ucy.ac.cy/handle/7/52993
dc.description.abstractThe aim of this study was to identify the molecular mechanism of action of the isoflavone, genistein. Genistein at 0.15 mM caused MCF-7 apoptotic cell death, which was accompanied by cell cycle delay in the G2/M phase. Twenty-four hours post-treatment, 47.3% of the MCF-7 cells accumulated at G2/M, compared with 19.9% in the untreated controls. At 0.15 mM, genistein caused an increase in the steady-state levels of the wild-type tumour suppressor p53, which was attributed to stabilising the tumour suppressor protein, since p53 mRNA levels did not increase. Prior to the upregulation of p53, which became evident within 6 h of genistein treatment, there was increased bcl-2 phosphorylation at 30 min post-treatment. Although early changes (30-120 min) in the phosphotyrosine peptide patterns were not detected, after 24h, genistein inhibited phosphorylation of several peptides. These results suggest that genistein's dual roles of protein tyrosine kinase inhibitor and topoisomerase II inhibitor are essential for the initiation of apoptosis.en
dc.sourceEuropean journal of canceren
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0032213459&doi=10.1016%2fS0959-8049%2898%2900198-1&partnerID=40&md5=17ea8070d840027330187bd47cc7dc85
dc.subjectarticleen
dc.subjectAntineoplastic Agentsen
dc.subjectcancer chemotherapyen
dc.subjecthumanen
dc.subjectAdenocarcinomaen
dc.subjectHumansen
dc.subjectBreast Neoplasmsen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectpriority journalen
dc.subjectprotein bcl 2en
dc.subjectprotein p53en
dc.subjectTumor Suppressor Protein p53en
dc.subjectProto-Oncogene Proteins c-bcl-2en
dc.subjectdrug mechanismen
dc.subjectApoptosisen
dc.subjecthuman cellen
dc.subjectestrogen activityen
dc.subjectbreast adenocarcinomaen
dc.subjecttumor suppressor geneen
dc.subjectUp-Regulationen
dc.subjectDown-Regulationen
dc.subjectPhosphorylationen
dc.subjectgene repressionen
dc.subjectBcl-2en
dc.subjectprotein phosphorylationen
dc.subjectdaidzeinen
dc.subjectTumor Cells, Cultureden
dc.subjectcell cycle g2 phaseen
dc.subjectBlotting, Northernen
dc.subjectBlotting, Westernen
dc.subjectcell levelen
dc.subjectcell strain mcf 7en
dc.subjectGenisteinen
dc.subjectimmunoblottingen
dc.subjectP53en
dc.subjectTopoisomeraseen
dc.titleGenistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cellsen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/S0959-8049(98)00198-1
dc.description.volume34
dc.description.startingpage1927
dc.description.endingpage1934
dc.author.facultyΣχολή Θετικών και Εφαρμοσμένων Επιστημών / Faculty of Pure and Applied Sciences
dc.author.departmentΤμήμα Βιολογικών Επιστημών / Department of Biological Sciences
dc.type.uhtypeArticleen
dc.description.notes<p>Manufacturers: indofine, United Statesen
dc.description.notesCited By :94</p>en
dc.source.abbreviationEur.J.Canceren
dc.contributor.orcidConstantinou, Andreas I. [0000-0003-0365-1821]
dc.gnosis.orcid0000-0003-0365-1821


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record